HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Obesity · Oral GLP-1 receptor agonist Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Obesity · Oral GLP-1 receptor agonist Therapeutic Area Assessment

27 signals · 7 insights · 69 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 81%

Evidence

103 items

Sources

3

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Obesity · Oral GLP-1 receptor agonist integrates 27 signals, 7 executive insights, and 69 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 13, 2026

    Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation

    The Allurion Gastric Balloon may cause serious complications, including gastric outlet obstruction, small bowel obstruction, and gastric perforation.

    View detail
  2. signalJul 12, 2026

    FDA Approves Supplemental Application for Wegovy (Semaglutide)

    The FDA has approved a supplemental application for Wegovy, a drug containing semaglutide, submitted by Novo.

    View detail
  3. signalJun 26, 2026

    Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program

    The Medicare GLP-1 Bridge program will provide access to Lilly's obesity treatments, Foundayo and Zepbound, for eligible Medicare Part D patients starting July 1.

    View detail
  4. signalJun 22, 2026

    Semaglutide tablet approved in the UK for weight loss

    The semaglutide tablet has received approval from the MHRA for weight loss and management in the UK.

    View detail
  5. regulatoryJul 21, 2026

    FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    Application ANDA204021. Sponsor: NOVEL LABS INC. Submission status: AP. Submission type: SUPPL. Active ingredients: OXYCODONE HYDROCHLORIDE.

    View detail
  6. regulatoryJul 21, 2026

    FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)

    Application ANDA202144. Sponsor: ACTAVIS LABS FL INC. Submission status: AP. Submission type: SUPPL. Active ingredients: HYDROMORPHONE HYDROCHLORIDE.

    View detail
  7. regulatoryJul 21, 2026

    FDA AP — COLESTIPOL HYDROCHLORIDE (SUPPL)

    Application ANDA077510. Sponsor: IMPAX LABS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: COLESTIPOL HYDROCHLORIDE.

    View detail
  8. regulatoryJul 21, 2026

    FDA AP — BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (SUPPL)

    Application ANDA205806. Sponsor: DR REDDYS LABS SA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE.

    View detail
  9. insightJul 13, 2026

    Regulatory Risks and Market Dynamics for Allurion Gastric Balloon Safety Concerns

    The updated safety information regarding the Allurion Gastric Balloon highlights significant risks that could affect patient safety and market perception. This situation necessitates close monitoring of regulatory responses and potential shifts in competitive dynamics within the obesity treatment sector. Regulatory context from MHRA (MHRA safety review gives UK plasma donations go ahead) supports the near-term read. Assessment grounded in 18 ranked evidence items (4 high-relevance).

    View detail
  10. insightJun 26, 2026

    Lilly's Medicare GLP-1 Bridge Program Enhances Competitive Position in Obesity Market

    The introduction of the Medicare GLP-1 Bridge program significantly enhances access to Lilly's obesity treatments, potentially increasing their market share in a competitive landscape. This move could set a precedent for how obesity medications are accessed by Medicare patients, influencing future strategies across the sector. Regulatory context from MHRA (Notice: Register of authorised online sellers of medicines in Northern Ireland) supports the near-term read. Assessment grounded in 21 ranked evidence items (21 high-relevance).

    View detail
  11. insightJun 22, 2026

    Semaglutide Tablet Approval Enhances Competitive Position in Obesity Market

    The approval of the semaglutide tablet for weight loss in the UK represents a significant advancement in obesity treatment, enhancing its competitive position in the GLP-1 market. This development necessitates close monitoring of market dynamics and competitor strategies to leverage potential market share growth. Regulatory context from MHRA (First GLP-1 tablet for weight loss approved in the UK) supports the near-term read. Assessment grounded in 19 ranked evidence items (7 high-relevance).

    View detail
  12. insightJun 17, 2026

    Eli Lilly Gains Competitive Edge in Obesity Market with Enhanced Access Strategies

    The coverage of Foundayo and Zepbound by CVS Caremark significantly enhances patient access to these obesity treatments, positioning Eli Lilly favorably against its competitors. This move could lead to increased market share and revenue growth in the obesity pharmacotherapy sector. Regulatory context from MHRA (Lower dose needle-free allergy treatment approved for younger children) supports the near-term read. Assessment grounded in 20 ranked evidence items (20 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 7 risk-calibrated assessments for portfolio review. 69 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 7 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)

    66%

    Application ANDA204021. Sponsor: NOVEL LABS INC. Submission status: AP. Submission type: SUPPL. Active ingredients: OXYCODONE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — HYDROMORPHONE HYDROCHLORIDE (SUPPL)

    66%

    Application ANDA202144. Sponsor: ACTAVIS LABS FL INC. Submission status: AP. Submission type: SUPPL. Active ingredients: HYDROMORPHONE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — COLESTIPOL HYDROCHLORIDE (SUPPL)

    66%

    Application ANDA077510. Sponsor: IMPAX LABS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: COLESTIPOL HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (SUPPL)

    66%

    Application ANDA205806. Sponsor: DR REDDYS LABS SA. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • FDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)

    66%

    Application ANDA204982. Sponsor: ACTAVIS LABS FL INC. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: PHENTERMINE HYDROCHLORIDE, TOPIRAMATE.

    Source: FDA

    View evidence

  • FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

    83%

    Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to patients with obesity.

    Source: FDA

    View evidence

  • Regulatory Risks and Market Dynamics for Allurion Gastric Balloon Safety Concerns

    56%

    The updated safety information regarding the Allurion Gastric Balloon highlights significant risks that could affect patient safety and market perception. This situation necessitates close monitoring of regulatory responses and potential shifts in competitive dynamics within the obesity treatment sector. Regulatory context from MHRA (MHRA safety review gives UK plasma donations go ahead) supports the near-term read. Assessment grounded in 18 ranked evidence items (4 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Lilly's Medicare GLP-1 Bridge Program Enhances Competitive Position in Obesity Market

    92%

    The introduction of the Medicare GLP-1 Bridge program significantly enhances access to Lilly's obesity treatments, potentially increasing their market share in a competitive landscape. This move could set a precedent for how obesity medications are accessed by Medicare patients, influencing future strategies across the sector. Regulatory context from MHRA (Notice: Register of authorised online sellers of medicines in Northern Ireland) supports the near-term read. Assessment grounded in 21 ranked evidence items (21 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Semaglutide Tablet Approval Enhances Competitive Position in Obesity Market

    62%

    The approval of the semaglutide tablet for weight loss in the UK represents a significant advancement in obesity treatment, enhancing its competitive position in the GLP-1 market. This development necessitates close monitoring of market dynamics and competitor strategies to leverage potential market share growth. Regulatory context from MHRA (First GLP-1 tablet for weight loss approved in the UK) supports the near-term read. Assessment grounded in 19 ranked evidence items (7 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Eli Lilly Gains Competitive Edge in Obesity Market with Enhanced Access Strategies

    92%

    The coverage of Foundayo and Zepbound by CVS Caremark significantly enhances patient access to these obesity treatments, positioning Eli Lilly favorably against its competitors. This move could lead to increased market share and revenue growth in the obesity pharmacotherapy sector. Regulatory context from MHRA (Lower dose needle-free allergy treatment approved for younger children) supports the near-term read. Assessment grounded in 20 ranked evidence items (20 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Competitive Dynamics Intensify in Obesity Treatment Market with New Efficacy Data

    90%

    The recent findings on Foundayo's efficacy in reducing body weight among older adults with obesity could significantly enhance its market positioning. This data may influence competitive dynamics in the obesity treatment landscape, necessitating strategic adjustments in marketing and positioning. Regulatory context from MHRA (First GLP-1 tablet for weight loss approved in the UK) supports the near-term read. Assessment grounded in 23 ranked evidence items (23 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Emerging Competitive Landscape in Obesity Treatments: Key Trials and Strategic Implications

    89%

    The promising Phase 2b results for Pfizer's berobenatide indicate a significant advancement in obesity management, potentially positioning Pfizer as a leader in the GLP-1 receptor agonist market. The ability to offer a monthly dosing regimen could enhance patient adherence and expand market share in a competitive landscape focused on long-acting therapies. Regulatory context from MHRA (First GLP-1 tablet for weight loss approved in the UK) supports the near-term read. Assessment grounded in 13 ranked evidence items (13 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation

    Safety Signal

  • FDA Approves Supplemental Application for Wegovy (Semaglutide)

    Regulatory Approval

  • Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program

    Regulatory Approval

  • Semaglutide tablet approved in the UK for weight loss

    Regulatory Approval

  • CVS Caremark to cover Foundayo and Zepbound, enhancing access for obesity treatment

    Competitive Move

  • Foundayo shows significant weight reduction in older adults with obesity in new analysis

    Trial Update

  • Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial

    Trial Update

  • Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

    Trial Update

Insights

  • Regulatory Risks and Market Dynamics for Allurion Gastric Balloon Safety Concerns

    Obesity · Medical Device

  • Lilly's Medicare GLP-1 Bridge Program Enhances Competitive Position in Obesity Market

    Obesity · GLP-1 Agonists

  • Semaglutide Tablet Approval Enhances Competitive Position in Obesity Market

    Obesity · GLP-1

  • Eli Lilly Gains Competitive Edge in Obesity Market with Enhanced Access Strategies

    Obesity · Pharmacotherapy

  • Competitive Dynamics Intensify in Obesity Treatment Market with New Efficacy Data

    Obesity · Oral GLP-1 receptor agonist

  • Emerging Competitive Landscape in Obesity Treatments: Key Trials and Strategic Implications

    Obesity · GLP-1 Receptor Agonist

  • Roche and Eli Lilly's Competitive Advances in Obesity Treatment Landscape

    Obesity · GLP-1/GIP Receptor Agonist and Amylin Analog

Companies

  • Roche

    212 signals

  • Pfizer

    140 signals

  • Eli Lilly

    78 signals

  • Novo Nordisk

    9 signals

  • Biogen

    7 signals

  • Dr. Reddy's

    8 signals

  • Dr. Reddy's Labs

    4 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.